NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of “Moderate Buy” by Brokerages

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $36.75.

A number of brokerages have weighed in on NRXP. Ascendiant Capital Markets reaffirmed a “buy” rating and issued a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. D. Boral Capital restated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, January 5th. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Finally, HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st.

Institutional Trading of NRx Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals during the 3rd quarter worth approximately $39,000. One Wealth Management Investment & Advisory Services LLC boosted its stake in NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after acquiring an additional 12,950 shares during the last quarter. AdvisorShares Investments LLC boosted its stake in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after acquiring an additional 78,339 shares during the last quarter. Anson Funds Management LP grew its holdings in NRx Pharmaceuticals by 26.2% during the 3rd quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock worth $6,683,000 after acquiring an additional 420,129 shares during the period. Finally, Sjbenen Advisory LLC bought a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at $41,000. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $2.12 on Tuesday. The firm has a market cap of $62.75 million, a price-to-earnings ratio of -0.90 and a beta of 1.62. NRx Pharmaceuticals has a one year low of $1.58 and a one year high of $3.84. The stock’s fifty day simple moving average is $2.31 and its 200 day simple moving average is $2.68.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $6.83 million. On average, research analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.